Fanconi Anemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 93 Published: September 30, 2021 Report Code: GMDGDHC13084IDB

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fanconi Anemia – Drugs In Development, 2021, provides an overview of the Fanconi Anemia (Hematological Disorders) pipeline landscape.Fanconi anemia (fan-KO-nee uh-NEE-me-uh), or FA, is a rare, inherited blood disorder that leads to bone marrow failure. The disorder also is called Fanconi’s anemia. FA is a type of aplastic anemia. In aplastic anemia, the bone marrow stops making or doesn't make enough of all three types of blood cells. Low levels of the three types of blood cells can harm many of the body's organs, tissues, and systems. Treatment is recommended for significant cytopenias, such as hemoglobin less than 8 g/dL, platelets fewer than 500/μL.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fanconi Anemia – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Fanconi Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Fanconi Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fanconi Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 1, 2 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 3 and 2 molecules, respectively.

Fanconi Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Fanconi Anemia (Hematological Disorders).

– The pipeline guide reviews pipeline therapeutics for Fanconi Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Fanconi Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Fanconi Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Fanconi Anemia (Hematological Disorders)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Fanconi Anemia (Hematological Disorders).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Fanconi Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

  • Bellicum Pharmaceuticals Inc

    Boehringer Ingelheim International GmbH

    Elixirgen Therapeutics Inc

    Foresee Pharmaceuticals Co Ltd

    Novartis AG

    Rimedion Inc

    Rocket Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Fanconi Anemia – Overview

Fanconi Anemia – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Fanconi Anemia – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Fanconi Anemia – Companies Involved in Therapeutics Development

Bellicum Pharmaceuticals Inc

Boehringer Ingelheim International GmbH

Elixirgen Therapeutics Inc

Foresee Pharmaceuticals Co Ltd

Novartis AG

Rimedion Inc

Rocket Pharmaceuticals Inc

Fanconi Anemia – Drug Profiles

afatinib dimaleate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eltrombopag olamine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXG-34217 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fancalen – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FP-045 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapies to Activate FANCC and FANCG for Fanconi Anemia – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy 1 for Fanconi Anemia – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate FANC-A for Fanconi Anemia – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate FANCA for Fanconi Anemia – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate FANCA Protein for Fanconi Anemia – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JP-4039 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mozafancogene autotemcel – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rivogenlecleucel – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Fanconi Anemia – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fanconi Anemia – Dormant Projects

Fanconi Anemia – Product Development Milestones

Featured News & Press Releases

May 13, 2021: Rocket Pharmaceuticals presents positive clinical data of mozafancogene autotemcel at 24th Annual Meeting of the American Society of Gene and Cell Therapy

Dec 07, 2020: Rocket Pharmaceuticals presents positive clinical data from its Fanconi Anemia Program at the 62nd American Society of Hematology annual meeting

May 12, 2020: Rocket Pharmaceuticals presents positive updates on RP-L102 program at the 23rd annual meeting of the American Society of Gene and Cell Therapy

Feb 24, 2020: Rocket Pharmaceuticals announces publication of manuscript evaluating mosaicism in Fanconi anemia

Dec 16, 2019: Rocket Pharmaceuticals receives the European Medicines Agency PRIME eligibility for RP-L102 gene therapy for Fanconi anemia

Dec 08, 2019: Rocket Pharmaceuticals presents promising preliminary results from phase 1 trial of commercial-grade RP-L102 “Process B” for Fanconi Anemia at 61st American Society of Hematology Annual Meeting

Dec 06, 2019: Rocket pharmaceuticals announces first patient treated in global registrational phase 2 study of RP-L102 “process B” for Fanconi anemia

Nov 06, 2019: Rocket Pharmaceuticals to present preliminary phase 1 data of RP-L102 “Process B” for Fanconi Anemia at the 61st American Society of Hematology Annual Meeting

Oct 24, 2019: Rocket Pharmaceuticals presents first evidence of long-term improvement and stabilization in blood counts and durable mosaicism in RP-L102 “Process A” for Fanconi Anemia

Oct 15, 2019: Rocket Pharmaceuticals announces upcoming presentation on Gene Therapy 1 for Fanconi Anemia at the European Society of Gene and Cell Therapy Annual Congress

Sep 10, 2019: Rocket Pharmaceuticals announces publication of data from phase 1/2 trial of first-generation RP-L102 for Fanconi Anemia in Nature Medicine

Sep 04, 2019: Rocket Pharmaceuticals announces registration-enabling phase 2 plans for RP-L102 gene therapy for Fanconi anemia following a supportive end-of-phase 1 FDA meeting

Aug 22, 2019: Rocket Pharmaceuticals announces clearance from the Spanish Agency for Medicines and Health Products for the phase 2 registration-enabling FANCOLEN-II study of RP-L102 for Fanconi Anemia

Apr 15, 2019: Rocket Pharmaceuticals announces upcoming presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting

Mar 12, 2019: Rocket Pharmaceuticals announces first patient dosed in phase 1 clinical trial of RP-L102 in the U.S.

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Fanconi Anemia, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Fanconi Anemia – Pipeline by Bellicum Pharmaceuticals Inc, 2021

Fanconi Anemia – Pipeline by Boehringer Ingelheim International GmbH, 2021

Fanconi Anemia – Pipeline by Elixirgen Therapeutics Inc, 2021

Fanconi Anemia – Pipeline by Foresee Pharmaceuticals Co Ltd, 2021

Fanconi Anemia – Pipeline by Novartis AG, 2021

Fanconi Anemia – Pipeline by Rimedion Inc, 2021

Fanconi Anemia – Pipeline by Rocket Pharmaceuticals Inc, 2021

Fanconi Anemia – Dormant Projects, 2021

List of Figures

List of Figures

Number of Products under Development for Fanconi Anemia, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.